Nurturing and launching new ventures is a key component of Enterprise Innovation’s business development strategies. In addition to development and dissemination of Weill Cornell Medicine technologies, these new venture creation efforts contribute to the expansion of New York City as a burgeoning biotech hub and many of Weill Cornell Medicine startups are rooted in New York.
By translating groundbreaking research into innovative care through new venture creation, we not only revolutionize diagnostics, treatments and health-care solutions for patients but also create new job opportunities and fuel local economic growth.
Weill Cornell Startups by the Numbers Through FY2023
Our startups have received funding from top-tier investors including Alexandria Venture Investments, ARCH Venture Partners, Longitude Capital, Omega Funds, OrbiMed, Morningside, Polaris Partners, RA Capital Management, Sofinnova Partners and Versant Ventures. We regularly work with incubators, accelerators, angels, entrepreneurs and funders of all sizes to incubate our startup opportunities.
We invite you to explore our current portfolio of companies. Connect with us to learn more about launching new ventures out of Weill Cornell Medicine, investing in our current portfolio companies, and supporting our entrepreneurial ecosystem.
We also encourage prospective partners to check out the rich portfolio of Cornell University startups across several industry categories, including biotechnology, diagnostics, food tech, agtech, semiconductors, manufacturing, hardware and production tools. Visit https://ctl.cornell.edu/new-ventures/cornell-startups/.